Research Topics
| J DingemanseSummaryAffiliation: University of Basel Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between caucasian and Japanese subjectsJasper Dingemanse
Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Allschwil, Switzerland
Br J Clin Pharmacol 61:405-13. 2006..To investigate the pharmacokinetics, pharmacodynamics and tolerability of the dual endothelin receptor antagonist tezosentan in caucasian and Japanese subjects...
Comparative tolerability, pharmacodynamics, and pharmacokinetics of a metabolite of a quinolizinone hypnotic and zolpidem in healthy subjectsJ Dingemanse
Jacor Research, Bottmingen, Switzerland
Drug Metab Dispos 28:1411-6. 2000..The relatively slow absorption of Ro 41-3290 (t(max) approximately 2.5 h) and the concentration-effect time delay do not make it a good candidate to replace its parent compound Ro 41-3696 as an investigational hypnotic...- Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarinJasper Dingemanse
Jacor Research, Bottmingen, Switzerland
Br J Clin Pharmacol 53:485-91. 2002..To investigate the influence of a multiple-dose regimen with the catechol-O-methyltransferase inhibitor entacapone on the pharmacokinetics and pharmacodynamics of warfarin... - Pharmacokinetic studies with a dual-release formulation of levodopa, a novel principle in the treatment of Parkinson's diseaseJ Dingemanse
Clin Pharma Research Ltd, Birsfelden, Switzerland
Eur Neurol 39:119-24. 1998..In conclusion, the release characteristics in healthy subjects of the new levodopa/benserazide formulation are influenced only to a minor extent by concomitant intake of food or by tablet breaking... - Multiple-dose tolerability, pharmacodynamics, and pharmacokinetics of the quinolizinone hypnotic Ro 41-3696 in elderly subjectsJ Dingemanse
Jacor Research, Bottmingen, Switzerland
Clin Neuropharmacol 24:82-90. 2001.... - Clinical pharmacology of bosentan, a dual endothelin receptor antagonistJasper Dingemanse
Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
Clin Pharmacokinet 43:1089-115. 2004..In a pharmacokinetic-pharmacodynamic study in PAH patients, the haemodynamic effects lagged the plasma concentrations of bosentan... - Comparative investigation of the pharmacokinetics of bosentan in Caucasian and Japanese healthy subjectsPaul L M van Giersbergen
Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Gewerbestrasse 18, 4123 Allschwil, Switzerland
J Clin Pharmacol 45:42-7. 2005..The results suggest that, based on pharmacokinetic grounds, no dose adjustment of bosentan is necessary when used to treat Japanese patients in comparison to Caucasian patients... - Tolerability, pharmacokinetics, and pharmacodynamics of clazosentan, a parenteral endothelin receptor antagonistPaul L M van Giersbergen
Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Gewerbestrasse 18, 4123 Allschwil, Switzerland
Eur J Clin Pharmacol 63:151-8. 2007..The purpose of this study was to investigate in healthy male subjects the tolerability, pharmacokinetics, and pharmacodynamics of ascending doses of clazosentan, an intravenous endothelin receptor antagonist... - Influence of food intake on the pharmacokinetics of miglustat, an inhibitor of glucosylceramide synthasePaul L M van Giersbergen
Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Gewerbestrasse 16, 4123 Allschwil, Switzerland
J Clin Pharmacol 47:1277-82. 2007..The observed effects of food intake on the pharmacokinetics of miglustat are not considered to be of clinical relevance... - Mutual pharmacokinetic interactions between steady-state bosentan and sildenafilGary Burgess
PGRD, Pfizer Ltd, Sandwich, Kent, UK
Eur J Clin Pharmacol 64:43-50. 2008.... - The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failureGad Cotter
The Cardiology Department, Assaf Harofeh Medical Center, 70300 Zerifin, Israel
Eur J Heart Fail 6:601-9. 2004..v.)-balanced dual endothelin (ET-A/B) antagonist, in doses of 50 and 100 mg/h, improved the hemodynamics but not the clinical outcome of patients with acute heart failure (AHF)... - Multiple-dose pharmacokinetics of intranasally administered IS-159 in healthy subjectsPaul L M van Giersbergen
The Medicines Company, Gasstrasse 1, CH-4056 Basel, Switzerland
Eur J Drug Metab Pharmacokinet 28:49-54. 2003..The results showed dose-proportional pharmacokinetics of IS-159 in the dose range tested and a low propensity for drug accumulation... - Investigation of the mutual pharmacokinetic interactions between bosentan, a dual endothelin receptor antagonist, and simvastatinJasper Dingemanse
Department of Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
Clin Pharmacokinet 42:293-301. 2003..In vitro, bosentan has been shown to be a mild inducer of cytochrome P450 (CYP) 2C9 and 3A4... - Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazolePaul L M van Giersbergen
Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Gewerbestrasse 18, 4123 Allschwil, Switzerland
Br J Clin Pharmacol 53:589-95. 2002..The present study was conducted to characterize the single- and multiple-dose pharmacokinetics of bosentan, a dual endothelin receptor antagonist, and to investigate a possible pharmacokinetic interaction with ketoconazole... - Entry-into-humans study with tezosentan, an intravenous dual endothelin receptor antagonistJasper Dingemanse
Actelion Pharmaceuticals Ltd, Department of Preclinical Pharmacology, Allschwil, Switzerland
J Cardiovasc Pharmacol 39:795-802. 2002..Tezosentan warrants further clinical development in view of its tolerability and pharmacokinetic profile, which appears advantageous for application in emergency situations... - Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjectsJasper Dingemanse
Actelion Pharmaceuticals Ltd, Department of Preclinical Pharmacology, Gewerbestrasse 18, 4123 Allschwil, Switzerland
Br J Clin Pharmacol 53:355-62. 2002..The purpose of this study was to investigate the tolerability, pharmacokinetics, and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, during chronic infusions in healthy male subjects... - In vivo and in vitro studies exploring the pharmacokinetic interaction between bosentan, a dual endothelin receptor antagonist, and glyburidePaul L M van Giersbergen
Department of Preclinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland
Clin Pharmacol Ther 71:253-62. 2002..This study was conducted to investigate a possible pharmacokinetic interaction between bosentan and glyburide... - Influence of food intake and formulation on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonistJasper Dingemanse
Actelion Pharmaceuticals Ltd, Department of Clinical Pharmacology, Allschwil, Switzerland
J Clin Pharmacol 42:283-9. 2002..In conclusion, bosentan bioavailability from the newly developed 125 mg tablet formulation is similar to that of the suspension, and food intake does not influence its pharmacokinetics to a clinically relevant extent... 
Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjectsRebecca E Wrishko
Lilly Research Laboratories, Lilly Corporate Center, DC 0730, Indianapolis, IN 46285, USA
J Clin Pharmacol 48:610-8. 2008..In conclusion, after 10 days of coadministration, bosentan decreased tadalafil exposure by 41.5% with minimal and clinically irrelevant differences (<20%) in bosentan exposure...